Clinical Trial Update: Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial [NA]

View source ↗

Summary

Prospective Phase II trial evaluating tislelizumab in combination with chemotherapy and response-adapted radiotherapy for de novo metastatic nasopharyngeal carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Chongqing University Cancer Hospital | Conditions: Nasopharyngeal Cancinoma (NPC) | NA | Status: ACTIVE_NOT_RECRUITING